Indian Journal of Dermatology
CORRESPONDENCE
Year
: 2021  |  Volume : 66  |  Issue : 3  |  Page : 330-

Bacillus calmette–Guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study


Mahmood Dhahir Al-Mendalawi 
 Department of Paediatrics, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq

Correspondence Address:
Mahmood Dhahir Al-Mendalawi
Department of Paediatrics, Al-Kindy College of Medicine, University of Baghdad, Baghdad
Iraq




How to cite this article:
Al-Mendalawi MD. Bacillus calmette–Guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study.Indian J Dermatol 2021;66:330-330


How to cite this URL:
Al-Mendalawi MD. Bacillus calmette–Guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study. Indian J Dermatol [serial online] 2021 [cited 2021 Sep 19 ];66:330-330
Available from: https://www.e-ijd.org/text.asp?2021/66/3/330/321341


Full Text



Sir,

I read the distinguished study by Jaisinghani et al.[1] published in the March–April 2019 issue of the Indian Journal of Dermatology. The authors found that the intralesional bacillus Calmette–Guerin (BCG) vaccine immunotherapy could be considered a promising, safe, and effective treatment modality for recurrent multiple warts.[1] I assume that the following concern might clinically curtail advocating that new modality in the clinical setting. It is worthy to mention that the precise diagnosis of tuberculosis (TB) is an essential step in the TB control program, particularly in the developing countries. Tuberculin skin test (TST) is considered a critical element in the diagnostic battery of TB. Studies have shown that the TST interpretation is affected by prior history of BCG vaccination.[2],[3],[4] With the notion that TB is still globally a substantial health hazard, particularly in the developing countries,[5] I assume that implementing intralesional BCG vaccine immunotherapy in treating warts might subsequently halt employing TST in the diagnosis of TB in suspected patients. Hence, weighing the benefit–risk ratio of this treatment modality ought to be exercised before its final recommendation in the clinical field. Additional clinical and immunological studies are suggested.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Jaisinghani AK, Dey VK, Suresh MS, Saxena A. Bacillus Calmette–Guerin immunotherapy for recurrent multiple warts: An open-label uncontrolled study. Indian J Dermatol 2019;64:164.
2Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-9.
3Subramani R, Datta M, Swaminathan S. Does effect of BCG vaccine decrease with time since vaccination and increase tuberculin skin test reaction? Indian J Tuberc 2015;62:226-9.
4Mancuso JD, Mody RM, Olsen CH, Harrison LH, Santosham M, Aronson NE. The long-term effect of Bacille Calmette-Guérin vaccination on tuberculin skin testing: A 55-year follow-up study. Chest 2017;152:282-94.
5Khan MK, Islam MN, Ferdous J, Alam MM. An overview on epidemiology of tuberculosis. Mymensingh Med J 2019;28:259-26.